{
    "address1": "Jinchuang Plaza",
    "address2": "Building 1, Fourth Floor 4560 Jinke Road Pudong",
    "city": "Shanghai",
    "zip": "201210",
    "country": "China",
    "phone": "86 21 6163 2588",
    "website": "https://www.zailaboratory.com",
    "industry": "Biotechnology",
    "industryDisp": "Biotechnology",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00efve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.",
    "fullTimeEmployees": 2036,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Dr. Ying  Du Ph.D.",
            "age": 56,
            "title": "Founder, Chairperson & CEO",
            "yearBorn": 1966,
            "fiscalYear": 2022,
            "totalPay": 1667101,
            "exercisedValue": 0,
            "unexercisedValue": 4758112
        },
        {
            "maxAge": 1,
            "name": "Mr. Joshua L.  Smiley",
            "age": 52,
            "title": "Pres & COO",
            "yearBorn": 1970,
            "fiscalYear": 2022,
            "totalPay": 647109,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Rafael G.  Amado M.D.",
            "age": 58,
            "title": "Pres and Head of Global Oncology R&D",
            "yearBorn": 1964,
            "fiscalYear": 2022,
            "totalPay": 477000,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Harald  Reinhart M.D.",
            "age": 70,
            "title": "Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases",
            "yearBorn": 1952,
            "fiscalYear": 2022,
            "totalPay": 923330,
            "exercisedValue": 68601,
            "unexercisedValue": 1779
        },
        {
            "maxAge": 1,
            "name": "Dr. Yajing  Chen Ph.D.",
            "title": "Chief Financial Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Peter  Huang Ph.D.",
            "title": "Chief Scientific Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Frazor Titus  Edmondson III, J.D.",
            "age": 56,
            "title": "Chief Legal Officer & Corp. Sec.",
            "yearBorn": 1966,
            "fiscalYear": 2021,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Ann E.  Beasley J.D.",
            "title": "Chief Compliance Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Ning  Xu M.D.",
            "age": 57,
            "title": "Exec. VP & Head of Clinical Operations",
            "yearBorn": 1965,
            "fiscalYear": 2018,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Jonathan J.  Wang MBA, Ph.D.",
            "age": 40,
            "title": "Chief Bus. Officer",
            "yearBorn": 1982,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 27.33,
    "open": 27.1,
    "dayLow": 25.905,
    "dayHigh": 27.3,
    "regularMarketPreviousClose": 27.33,
    "regularMarketOpen": 27.1,
    "regularMarketDayLow": 25.905,
    "regularMarketDayHigh": 27.3,
    "payoutRatio": 0.0,
    "beta": 1.11065,
    "forwardPE": -8.85906,
    "volume": 301774,
    "regularMarketVolume": 301774,
    "averageVolume": 500391,
    "averageVolume10days": 635540,
    "averageDailyVolume10Day": 635540,
    "bid": 0.0,
    "ask": 0.0,
    "bidSize": 800,
    "askSize": 800,
    "marketCap": 2705208064,
    "fiftyTwoWeekLow": 20.975,
    "fiftyTwoWeekHigh": 52.48,
    "priceToSalesTrailing12Months": 10.743437,
    "fiftyDayAverage": 27.0807,
    "twoHundredDayAverage": 33.158226,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "enterpriseValue": 1729218560,
    "profitMargins": -1.56075,
    "floatShares": 88042479,
    "sharesOutstanding": 98838704,
    "sharesShort": 3147347,
    "sharesShortPriorMonth": 2946898,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.0318,
    "heldPercentInsiders": 0.01825,
    "heldPercentInstitutions": 0.58551,
    "shortRatio": 7.24,
    "impliedSharesOutstanding": 102470000,
    "bookValue": 9.626,
    "priceToBook": 2.742572,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "netIncomeToCommon": -392998016,
    "trailingEps": -3.84,
    "forwardEps": -2.98,
    "pegRatio": 0.1,
    "enterpriseToRevenue": 6.867,
    "enterpriseToEbitda": -4.481,
    "52WeekChange": -0.48926294,
    "SandP52WeekChange": 0.08443928,
    "exchange": "NGM",
    "quoteType": "EQUITY",
    "symbol": "ZLAB",
    "underlyingSymbol": "ZLAB",
    "shortName": "Zai Lab Limited",
    "longName": "Zai Lab Limited",
    "firstTradeDateEpochUtc": 1505914200,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "8abb8ada-ed23-324a-aac0-9a720ac3e08a",
    "messageBoardId": "finmb_271123063",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 26.4,
    "targetHighPrice": 130.0,
    "targetLowPrice": 40.65,
    "targetMeanPrice": 72.3,
    "targetMedianPrice": 66.5,
    "recommendationMean": 1.7,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 12,
    "totalCash": 874654976,
    "totalCashPerShare": 8.933,
    "ebitda": -385892992,
    "totalDebt": 19054000,
    "quickRatio": 7.069,
    "currentRatio": 7.63,
    "totalRevenue": 251800992,
    "debtToEquity": 2.044,
    "revenuePerShare": 2.619,
    "returnOnAssets": -0.19548,
    "returnOnEquity": -0.36652002,
    "grossProfits": -145386000,
    "freeCashflow": -272515264,
    "operatingCashflow": -363604000,
    "revenueGrowth": 0.429,
    "grossMargins": -0.49995,
    "ebitdaMargins": -1.5325301,
    "operatingMargins": -1.56829,
    "financialCurrency": "USD",
    "trailingPegRatio": null,
    "parent_etfs": [
        "CHB"
    ]
}